Total
0
Shares
PharmAust (ASX:PAA) - Chief Scientific Officer, Richard Mollard - The Market Herald
Chief Scientific Officer, Richard Mollard
Source: PharmAust
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • In collaboration with three independent laboratories, PharmAust (PAA) has investigated the effects of monepantel (MPL) and monepantel sulfone (MPLS) on SARS-CoV2 infection, the causal agent of COVID-19  
  • All three labs demonstrated both MPL and MPLS protection against cell death in vitro following infection with SAR-CoV2
  • PharmAust has been working with contract research organisations to explore European and UK evaluations for a Phase I trial in human patients to treat COVID-19, once the manufacture of monepantel tablets is complete
  • PharmAust was up 8.25 per cent, trading at 10.5 cents per share at 2:30 pm AEST

In collaboration with three independent laboratories, PharmAust (PAA) has investigated the effects of its monepantel (MPL) and monepantel sulfone (MPLS) on SARS-CoV2 infection, the causal agent of COVID-19.  

The three labs investigated SARS-CoV2-induced cell death, SARS-CoV2 RNA release from the cell and SARS-CoV2 RNA infection of neighbouring cells.

All three investigations demonstrated both monepantel (MPL) and monepantel sulfone (MPLS) protect against cell death in vitro, following infection with SARS-CoV2.

Monepantel, the company’s lead drug candidate, is a potent and safe treatment that has been shown to have key influences in cancer growth, neurodegenerative diseases and viral infections. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs.

Two laboratories also investigated the effects of MPL and MPLS on early stages of the lifecycle by examining RNA release into the culture media.

One study proved both MPL and MPLS showed an around 50 per cent decrease of SARS-CoV2 viral RNA, while another saw the virus decrease by up to 70 per cent.

While preparing for clinical trials, PharmAust says it will continue to analyse data to understand optimal use of MPL as an anti-viral therapeutic.

PharmAust has been working with contract research organisations to explore European and United Kingdom evaluations for a Phase I trial in human patients to treat COVID-19, once manufacture of GMP-grade monepantel tablets is complete.

PharmAust was up 8.25 per cent, trading at 10.5 cents per share at 2:30 pm AEST.    

PAA by the numbers
More From The Market Herald
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon - The Market Herald

" ImpediMed (ASX:IPD) initiates SOZO heart failure program

ImpediMed (IPD) has initiated its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago.    
Invex Therapeutics (ASX:IXC) - Chairman, Jason Loveridge - The Market Herald

" Invex Therapeutics (ASX:IXC) pens agreement for commercialisation of Presedin

Invex Therapeutics (IXC) has signed an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure.
LBT Innovations (ASX:LBT) - CEO and MD, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) subsidiary appoints US distributor

LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture System (CCS), has appointed Thermo Fisher Scientific as its US distributor.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett - The Market Herald

" Paradigm Biopharma (ASX:PAR) receives FDA feedback for knee osteoarthritis drug

Paradigm Biopharmaceuticals (PAR) has received feedback from US Food and Drug Administration (FDA) for its knee osteoarthritis drug.